High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

Paula Vainio, Laura Lehtinen, Mika Hilvo, T. Mirtti, John Mpindi, Pekka Kohonen, Vidal Fey, Kirsi Ketola, K. Alanen, Merja Perälä, Matej Oresic, Olli Kallioniemi, Kristiina Iljin

    Research output: Contribution to conferenceConference articleScientific

    Original languageEnglish
    Publication statusPublished - 2010
    MoE publication typeNot Eligible
    EventInsights in Cancer Progression and Invasion - Helsinki, Finland
    Duration: 3 Jun 20104 Jun 2010

    Conference

    ConferenceInsights in Cancer Progression and Invasion
    CountryFinland
    CityHelsinki
    Period3/06/104/06/10

    Cite this

    Vainio, P., Lehtinen, L., Hilvo, M., Mirtti, T., Mpindi, J., Kohonen, P., Fey, V., Ketola, K., Alanen, K., Perälä, M., Oresic, M., Kallioniemi, O., & Iljin, K. (2010). High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. Paper presented at Insights in Cancer Progression and Invasion, Helsinki, Finland.